Magenta Therapeutics, Inc. - FORM 10-K - EX-10.10.5 - March 3, 2021

Attached files

file filename
10-K - 10-K - Magenta Therapeutics, Inc.d76599d10k.htm
EX-31.1 - EX-31.1 - Magenta Therapeutics, Inc.d76599dex311.htm
EX-21.1 - EX-21.1 - Magenta Therapeutics, Inc.d76599dex211.htm
EX-10.10.7 - EX-10.10.7 - Magenta Therapeutics, Inc.d76599dex10107.htm
EX-23.1 - EX-23.1 - Magenta Therapeutics, Inc.d76599dex231.htm
EX-10.14.2 - EX-10.14.2 - Magenta Therapeutics, Inc.d76599dex10142.htm
EX-32.1 - EX-32.1 - Magenta Therapeutics, Inc.d76599dex321.htm
EX-31.2 - EX-31.2 - Magenta Therapeutics, Inc.d76599dex312.htm
EX-10.10.4 - EX-10.10.4 - Magenta Therapeutics, Inc.d76599dex10104.htm

Exhibit 10.10.5

AMENDMENT #3

TO

PROJECT RIDER #1

COLLABORATION AGREEMENT

This Amendment #3 to Project Rider #1 (“Amendment #3”) is entered into effective as of the date of the final signature executing this Amendment #3 (“Amendment #3 Effective Date”) by and between Magenta Therapeutics, Inc. (“Magenta”) and National Marrow Donor Program d/b/a Be The Match Biotherapies (“BTMB”) (each a “Party” and collectively the “Parties”).

WHEREAS, the Parties executed a Collaboration Agreement, effective November 10, 2017 and a Project Rider, effective December 6, 2017 (as amended by that certain Amendment #1, effective December 6, 2018 and Amendment #2, effective November 13, 2019, “Project Rider #1”); and

WHEREAS, the Parties agree to extend the Term and Payment Schedule of the Project Rider #1.

NOW, THEREFORE, for the valuable consideration contained herein, and intending to be legally bound, Magenta and BTMB agree to the following amendment as follows:

Amendment to Project Rider #1

 

1.

Delete the Payment Schedule in Section D. Compensation of BTMB of Project Rider #1 in its entirety and replace it with the following to read as follows:

PAYMENT SCHEDULE

 

For Services provided by BTMB during Calendar Year 2021 (January 1, 2021 through December 31, 2021), Magenta will pay BTMB a fixed price quarterly payment of $17,500.   

BTMB will invoice $17,500 every January 15th for consulting services occurring during the period commencing January 1st and ending March 31st.

 

BTMB will invoice $17,500 every April 15th for consulting services commencing April 1st and ending June 30th.

 

BTMB will invoice $17,500 every July 15th for consulting services commencing July 1st and ending September 30th.

 

BTMB will invoice $17,500 every October 15th for consulting services commencing October 1st and ending December 31st.

2.

Delete Section E. TERM. of Project Rider #1 in its entirety and replace it with the following to read as follows:

E. TERM. The term of this Rider shall commence on the Rider effective date set forth above and continue and remain in effect through December 31, 2021.

[Remainder of page intentionally left blank.]

 

2

This Amendment #3 is executed by individuals who are duly authorized to legally bind their respective parties as of the Amendment #3 Effective Date:

 

MAGENTA THERAPEUTICS, INC.    

NATIONAL MARROW DONOR

PROGRAM d/b/a BE THE MATCH

BIOTHERAPIES

By:   /s/ Christina Isacson     By:   /s/ Mary Frey
  Authorized signature       Authorized signature
 

Christina Isacson

      

Mary Frey

  (Typed/Printed Name)       (Typed/Printed Name)
Title:  

Chief Business Officer

     Title:  

Contracts & Procurement Director

Date:  

12/16/20

     Date:  

12/7/2020

 

3

Magenta Therapeutics, Inc. Reports